KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Receivables (2019 - 2025)

GoodRx Holdings (GDRX) has disclosed Receivables for 7 consecutive years, with $235.7 million as the latest value for Q4 2025.

  • Quarterly Receivables rose 61.54% to $235.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $235.7 million through Dec 2025, up 61.54% year-over-year, with the annual reading at $235.7 million for FY2025, 61.54% up from the prior year.
  • Receivables hit $235.7 million in Q4 2025 for GoodRx Holdings, up from $203.7 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $235.7 million in Q4 2025 to a low of $74.4 million in Q1 2021.
  • Historically, Receivables has averaged $136.9 million across 5 years, with a median of $123.3 million in 2022.
  • Biggest five-year swings in Receivables: soared 65.7% in 2022 and later decreased 5.55% in 2023.
  • Year by year, Receivables stood at $118.1 million in 2021, then dropped by 0.8% to $117.1 million in 2022, then rose by 22.59% to $143.6 million in 2023, then increased by 1.62% to $145.9 million in 2024, then soared by 61.54% to $235.7 million in 2025.
  • Business Quant data shows Receivables for GDRX at $235.7 million in Q4 2025, $203.7 million in Q3 2025, and $189.0 million in Q2 2025.